Ben-Gurion University of the Negev's Prof. Alon Monsonego had discovered that T helper lymphocytes, a subset of immune cells ...

The start of the trial marks an expansion of the firm's oncology pipeline, and the firm hopes mRNA-2808 will be the first of many T-cell engagers in its portfolio.

INB-619 demonstrated equivalent efficacy to the FDA approved, commercial T Cell Engagers (TCE) compounds, blinatumomab and mosunetuzumab, with ...

While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune ...

However, details of the intervening steps, as researchers have learned in the past 65 years, are quite complex — certain cells carry the flu antigen to the immune system, specific immune cells respond ...

Researchers at the First Affiliated Hospital of the University of Science and Technology of China claim that an in vivo CD8 T-cell-targeted lipid nanoparticle carrying CD19 CAR mRNA (HN2301) generated ...

There are two types of Tph cells in rheumatoid arthritis joints that have different roles. Stem-like Tph cells live inside immune “hubs” called tertiary lymphoid structures, where they interact ...

The company will focus on advancing a program in hematological malignancies and plans to launch a registrational trial in 2026.